Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria

2013 ◽  
Vol 37 (6) ◽  
pp. 1348-1355 ◽  
Author(s):  
Yun-Hsuan Lee ◽  
Cheng-Yuan Hsia ◽  
Chia-Yang Hsu ◽  
Yi-Hsiang Huang ◽  
Han-Chieh Lin ◽  
...  
2020 ◽  
Vol 272 (4) ◽  
pp. 574-581 ◽  
Author(s):  
Diamantis I. Tsilimigras ◽  
Rittal Mehta ◽  
Anghela Z. Paredes ◽  
Dimitrios Moris ◽  
Kota Sahara ◽  
...  

2010 ◽  
Vol 53 (1) ◽  
pp. 108-117 ◽  
Author(s):  
Chia-Yang Hsu ◽  
Yi-Hsiang Huang ◽  
Cheng-Yuan Hsia ◽  
Chien-Wei Su ◽  
Han-Chieh Lin ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Irvin Rexha ◽  
Fabian Laage-Gaupp ◽  
Julius Chapiro ◽  
Milena Anna Miszczuk ◽  
Johanna Maria Mijntje van Breugel ◽  
...  

AbstractThis study was designed to assess 3D vs. 1D and 2D quantitative tumor analysis for prediction of overall survival (OS) in patients with Intrahepatic Cholangiocarcinoma (ICC) who underwent conventional transarterial chemoembolization (cTACE). 73 ICC patients who underwent cTACE were included in this retrospective analysis between Oct 2001 and Feb 2015. The overall and enhancing tumor diameters and the maximum cross-sectional and enhancing tumor areas were measured on baseline images. 3D quantitative tumor analysis was used to assess total tumor volume (TTV), enhancing tumor volume (ETV), and enhancing tumor burden (ETB) (ratio between ETV and liver volume). Patients were divided into low (LTB) and high tumor burden (HTB) groups. There was a significant separation between survival curves of the LTB and HTB groups using enhancing tumor diameter (p = 0.003), enhancing tumor area (p = 0.03), TTV (p = 0.03), and ETV (p = 0.01). Multivariate analysis showed a hazard ratio of 0.46 (95%CI: 0.27–0.78, p = 0.004) for enhancing tumor diameter, 0.56 (95% CI 0.33–0.96, p = 0.04) for enhancing tumor area, 0.58 (95%CI: 0.34–0.98, p = 0.04) for TTV, and 0.52 (95%CI: 0.30–0.91, p = 0.02) for ETV. TTV and ETV, as well as the largest enhancing tumor diameter and maximum enhancing tumor area, reliably predict the OS of patients with ICC after cTACE and could identify ICC patients who are most likely to benefit from cTACE.


Sign in / Sign up

Export Citation Format

Share Document